Transcriptome Sequencing Across a Prostate Cancer Cohort Identifies PCAT-1, an Unannotated LincRNA Implicated in Disease Progression

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2011 Aug 2

PMID 21804560

Citations 606

Authors

John R Prensner

Matthew K Iyer

O Alejandro Balbin

Saravana M Dhanasekaran

Qi Cao

J Chad Brenner

Bharathi Laxman

Irfan A Asangani

Catherine S Grasso

Hal D Kominsky

Xuhong Cao

Xiaojun Jing

Xiaoju Wang

Javed Siddiqui

John T Wei

Daniel Robinson

Hari K Iyer

Nallasivam Palanisamy

Christopher A Maher

Arul M Chinnaiyan

Affiliations

Soon will be listed here.

Abstract

Noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the potential to serve as novel markers of disease and to reveal uncharacterized aspects of tumor biology. Here we discover 121 unannotated prostate cancer-associated ncRNA transcripts (PCATs) by ab initio assembly of high-throughput sequencing of polyA(+) RNA (RNA-Seq) from a cohort of 102 prostate tissues and cells lines. We characterized one ncRNA, PCAT-1, as a prostate-specific regulator of cell proliferation and show that it is a target of the Polycomb Repressive Complex 2 (PRC2). We further found that patterns of PCAT-1 and PRC2 expression stratified patient tissues into molecular subtypes distinguished by expression signatures of PCAT-1-repressed target genes. Taken together, our findings suggest that PCAT-1 is a transcriptional repressor implicated in a subset of prostate cancer patients. These findings establish the utility of RNA-Seq to identify disease-associated ncRNAs that may improve the stratification of cancer subtypes.

Citing Articles

Natural products and long non-coding RNAs in prostate cancer: insights into etiology and treatment resistance.

Elimam H, Zaki M, Abd-Elmawla M, Darwish H, Hatawsh A, Aborehab N Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39825964 DOI: 10.1007/s00210-024-03736-x.

The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.

Ram M, Fraser M, Vieira Dos Santos J, Tasakis R, Islam A, Abo-Donia J Pharmgenomics Pers Med. 2024; 17:573-609.

PMID: 39723112 PMC: 11669356. DOI: 10.2147/PGPM.S350238.

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer.

Zhu Z, Xuan W, Wang C, Li C Front Oncol. 2024; 14:1481777.

PMID: 39655078 PMC: 11625809. DOI: 10.3389/fonc.2024.1481777.

FunlncModel: integrating multi-omic features from upstream and downstream regulatory networks into a machine learning framework to identify functional lncRNAs.

Li Y, Qian F, Zhang G, Li X, Zhou L, Yu Z Brief Bioinform. 2024; 26(1).

PMID: 39602828 PMC: 11601888. DOI: 10.1093/bib/bbae623.

Association of lncRNA ANRIL rs10757278 A>G Variant, Tumor Size, Grading, Tumor Site, and Tumor Stage in Oral Squamous Cell Carcinoma Patients.

Salah M, Rezaee M, Fattahi M, Ghaderi A, Khademi B, Mokhtari M Rep Biochem Mol Biol. 2024; 13(1):59-66.

PMID: 39582818 PMC: 11580132. DOI: 10.61186/rbmb.13.1.59.

References

Yap K, Li S, Munoz-Cabello A, Raguz S, Zeng L, Mujtaba S . Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010; 38(5):662-74. PMC: 2886305. DOI: 10.1016/j.molcel.2010.03.021. View

Huttenhower C, Haley E, Hibbs M, Dumeaux V, Barrett D, Coller H . Exploring the human genome with functional maps. Genome Res. 2009; 19(6):1093-106. PMC: 2694471. DOI: 10.1101/gr.082214.108. View

Ahmadiyeh N, Pomerantz M, Grisanzio C, Herman P, Jia L, Almendro V . 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A. 2010; 107(21):9742-6. PMC: 2906844. DOI: 10.1073/pnas.0910668107. View

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

Dhanasekaran S, Barrette T, Ghosh D, Shah R, Varambally S, Kurachi K . Delineation of prognostic biomarkers in prostate cancer. Nature. 2001; 412(6849):822-6. DOI: 10.1038/35090585. View

Kim T, Hemberg M, Gray J, Costa A, Bear D, Wu J . Widespread transcription at neuronal activity-regulated enhancers. Nature. 2010; 465(7295):182-7. PMC: 3020079. DOI: 10.1038/nature09033. View

Yu J, Yu J, Mani R, Cao Q, Brenner C, Cao X . An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010; 17(5):443-54. PMC: 2874722. DOI: 10.1016/j.ccr.2010.03.018. View

He Y, Vogelstein B, Velculescu V, Papadopoulos N, Kinzler K . The antisense transcriptomes of human cells. Science. 2008; 322(5909):1855-7. PMC: 2824178. DOI: 10.1126/science.1163853. View

Robertson G, Schein J, Chiu R, Corbett R, Field M, Jackman S . De novo assembly and analysis of RNA-seq data. Nat Methods. 2010; 7(11):909-12. DOI: 10.1038/nmeth.1517. View

10.

Maher C, Palanisamy N, Brenner J, Cao X, Kalyana-Sundaram S, Luo S . Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A. 2009; 106(30):12353-8. PMC: 2708976. DOI: 10.1073/pnas.0904720106. View

11.

Olama A, Kote-Jarai Z, Giles G, Guy M, Morrison J, Severi G . Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet. 2009; 41(10):1058-60. DOI: 10.1038/ng.452. View

12.

Huarte M, Guttman M, Feldser D, Garber M, Koziol M, Kenzelmann-Broz D . A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010; 142(3):409-19. PMC: 2956184. DOI: 10.1016/j.cell.2010.06.040. View

13.

van Bakel H, Nislow C, Blencowe B, Hughes T . Most "dark matter" transcripts are associated with known genes. PLoS Biol. 2010; 8(5):e1000371. PMC: 2872640. DOI: 10.1371/journal.pbio.1000371. View

14.

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View

15.

Birney E, Stamatoyannopoulos J, Dutta A, Guigo R, Gingeras T, Margulies E . Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007; 447(7146):799-816. PMC: 2212820. DOI: 10.1038/nature05874. View

16.

Rubin M, Zhou M, Dhanasekaran S, Varambally S, Barrette T, Sanda M . alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002; 287(13):1662-70. DOI: 10.1001/jama.287.13.1662. View

17.

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

18.

Orom U, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G . Long noncoding RNAs with enhancer-like function in human cells. Cell. 2010; 143(1):46-58. PMC: 4108080. DOI: 10.1016/j.cell.2010.09.001. View

19.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

20.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-7. DOI: 10.1126/science.275.5308.1943. View